270 related articles for article (PubMed ID: 28104247)
1. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
Gündüz T; Kürtüncü M; Eraksoy M
Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
[No Abstract] [Full Text] [Related]
2. Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
Fragoso YD; Adoni T; Gomes S; Goncalves MVM; Parolin LF; Rosa G; Ruocco HH
Clin Drug Investig; 2019 Sep; 39(9):909-913. PubMed ID: 31152369
[TBL] [Abstract][Full Text] [Related]
3. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
4. Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
Forci B; Mariottini A; Mechi C; Massacesi L; Repice A
Mult Scler Relat Disord; 2017 Jul; 15():24-26. PubMed ID: 28641768
[TBL] [Abstract][Full Text] [Related]
5. [Fingolimod].
Hashi Y; Kondo T
Nihon Rinsho; 2015 Sep; 73 Suppl 7():205-11. PubMed ID: 26480701
[No Abstract] [Full Text] [Related]
6. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
[TBL] [Abstract][Full Text] [Related]
7. Herpes zoster: a potential risk associated with fingolimod treatment.
Mayor Ibarguren A; Gómez Fernández C; Tallón Barranco A; Fernández Fournier M; González Ramos J; Romero Gómez MP; Herranz Pinto P
Int J Dermatol; 2015 Sep; 54(9):e373-5. PubMed ID: 26173466
[No Abstract] [Full Text] [Related]
8. Polydermatomal perineal and gluteal herpes zoster infection in a patient on fingolimod treatment.
Kawiorski MM; Viedma-Guiard E; Costa-Frossard L; Corral I
Enferm Infecc Microbiol Clin; 2015 Feb; 33(2):138-9. PubMed ID: 24958672
[No Abstract] [Full Text] [Related]
9. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
Członkowska A; Smoliński Ł; Litwin T
Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
[TBL] [Abstract][Full Text] [Related]
10. Famous.
Kim MJ; Bhatti MT; Costello F
Surv Ophthalmol; 2016; 61(4):512-9. PubMed ID: 26742785
[TBL] [Abstract][Full Text] [Related]
11. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
12. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.
Artemiadis AK; Nikolaou G; Kolokythopoulos D; Tegos N; Terentiou A; Triantafyllou N; Papanastasiou I
Mult Scler; 2015 May; 21(6):795-6. PubMed ID: 25432949
[No Abstract] [Full Text] [Related]
13. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R
CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493
[No Abstract] [Full Text] [Related]
14. Persistent headache in patients with multiple sclerosis starting treatment with fingolimod.
Fragoso YD; Adoni T; Gomes S; Goncalves MV; Matta AP; Mendes MF; Siquineli F
Headache; 2015 Apr; 55(4):578-9. PubMed ID: 25754576
[No Abstract] [Full Text] [Related]
15. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: a case report and review of imaging findings.
Chong I; Wang KY; Lincoln CM
Clin Imaging; 2019; 54():53-56. PubMed ID: 30544079
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
[TBL] [Abstract][Full Text] [Related]
17. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
Bianco A; Patanella AK; Nociti V; De Fino C; Lucchini M; Savio FL; Rossini PM; Mirabella M
Mult Scler Relat Disord; 2016 Sep; 9():11-3. PubMed ID: 27645336
[TBL] [Abstract][Full Text] [Related]
18. Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis.
Ward MD; Jones DE; Goldman MD
Mult Scler Relat Disord; 2016 Sep; 9():47-9. PubMed ID: 27645342
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events.
Fragoso YD
Acta Neurol Belg; 2017 Dec; 117(4):821-827. PubMed ID: 28528469
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use.
Thoo S; Cugati S; Lee A; Chen C
Mult Scler; 2015 Feb; 21(2):249-51. PubMed ID: 24696055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
